This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Semaglutide added to automated insulin delivery in type 1 diabetes increased time in glucose target range by 4.8 percentage points without increasing hypoglycemia. Two cases of euglycemic ketosis occurred.
Why it matters
Type 1 diabetes management remains challenging even with insulin pumps. This is the first blinded trial showing semaglutide can improve glucose control in T1D when paired with automated insulin delivery.
The numbers in context
28 randomized, 24 completed. Time in range (3.9-10.0 mmol/L) increased 4.8 percentage points (SD 7.6, P = 0.006). No increase in time below 3.9 (P = 0.19) or 3.0 mmol/L (P = 0.65). No DKA or severe hypoglycemia. 2 euglycemic ketosis episodes. Max dose 1 mg.
How the study worked
Randomized, double-blind, crossover trial. Semaglutide titrated up to 1 mg over 11 weeks, then 4 weeks on automated insulin delivery. Primary endpoint: time in target glucose range during last 4 weeks.
Who was studied
Adults with type 1 diabetes using automated insulin delivery
What this study cannot tell us
Very small (28 randomized, 24 completed). Short treatment period (15 weeks total). Crossover design may have carryover effects. Euglycemic ketosis is a safety concern needing longer-term data.
Read the original research
Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.
Nature medicine, 31(4), 1239-1245
Citation
Pasqua, Melissa-Rosina; Tsoukas, Michael A; Kobayati, Alessandra; Aboznadah, Wedyan; Jafar, Adnan; Haidar, Ahmad. (2025). Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.. Nature medicine, 31(4), 1239-1245. https://doi.org/10.1038/s41591-024-03463-z